In-depth writing on data integrity, regulatory compliance, and AI tools for pharma and biotech.
How to assess a GxP computerized system against 21 CFR Part 11 and EU Annex 11 requirements. What each requirement means in practice, common gaps, and a structured approach to Part 11 compliance assessment.
Validation of automation systems in pharmaceutical manufacturing, PLC, SCADA, DCS, MES interfaces, recipes, alarms, audit trails, and what regulators expect from batch manufacturing control systems.
A practical guide to GMP batch record review, the process, what makes a batch record complete, how to conduct a meaningful review, common failures, and how automated systems change the picture.
A practical guide to computerized systems in clinical trials, EDC, IRT/RTSM, eTMF, CTMS, and safety databases. What validation means for clinical systems, what FDA and ICH E6 require, and what inspectors check in a BIMO inspection.
A detailed self-audit checklist for computer system validation programs, system inventory, validation documentation, testing evidence, change control, supplier management, and periodic review. Aligned with GAMP 5 Second Edition and FDA CSA final guidance.
A complete data integrity self-audit framework covering infrastructure controls, system configuration, procedural controls, work practice verification, and culture indicators. Structured to find what FDA inspectors find.
A practical guide to clinical QA, GCP requirements for data integrity, electronic data capture (EDC) validation, trial master file management, clinical audit strategy, and how clinical data quality connects to regulatory submissions.
How to approach validation for AI and machine learning systems in regulated pharmaceutical environments, what's different about AI validation, the current regulatory gaps, and a practical framework for getting it right now.
Practical lessons from building AI-assisted compliance tools in regulated pharma environments, where the hype ends and the useful stuff begins.
A practical guide to handling systems that have been in GxP use without proper validation, how to assess the risk, conduct a retrospective validation, manage the regulatory disclosure, and determine when a system needs replacement rather than remediation.
A practical guide to managing a DI remediation program after regulatory findings, organizing the response, prioritizing systemic remediation, managing inspector oversight, rebuilding trust with regulators, and transitioning from crisis to sustainable program. For quality directors and compliance leaders.
A complete methodology for conducting a GxP data integrity gap assessment, scoping the assessment, evaluating each system layer, scoring findings, producing a defensible report, and prioritizing remediation. For DI program leaders and quality directors.
Why data integrity violations happen in organizations with good procedures and trained people, organizational pressure, normalization of deviance, diffusion of responsibility, and the specific management behaviors that prevent or enable falsification. For quality leaders and compliance directors.
A strategic guide to data integrity and data package architecture for BLA submissions, CMC data organization, data integrity requirements for regulatory review, pre-BLA inspection readiness, and what the FDA reviewers and inspectors are actually looking for in the data.
A practical breakdown of FDA's data integrity expectations for gene therapy manufacturers, beyond the checklist, into the actual inspection findings.
How the scientific and regulatory characteristics of CGT create data integrity challenges that don't exist in conventional drug manufacturing, and what to do about them.
The practical operational controls required to maintain a computerized system in a validated state, handover, support services, incident management, change management, periodic review, backup and recovery, security, and archiving. Based on ISPE GAMP operational guidance.
A complete QMS self-audit framework, document control, deviation and CAPA management, change control, training, supplier qualification, internal audits, and quality metrics. Structured around ICH Q10 and FDA/EMA expectations.
A complete qualification audit checklist for pharmaceutical equipment and analytical instruments, DQ, IQ, OQ, PQ, calibration, maintenance, periodic review, and change control. Based on USP <1058>, EU Annex 15, and ISPE C&Q Baseline Guide.
A complete guide to pharmaceutical process validation using the modern three-stage lifecycle approach, process design, process qualification, and continued process verification, with practical detail on studies, documentation, statistics, and regulatory expectations.
A complete operational guide to pharmaceutical stability programs, ICH storage conditions, stability-indicating methods, shelf life determination, accelerated and long-term studies, ongoing stability, and what FDA and EMA reviewers look for in stability data packages.
A complete operational guide to cleaning validation, regulatory basis, ADE/PDE calculations, worst-case product selection, swab sampling design, acceptance criteria, and what FDA inspectors focus on.
A complete operational guide to out-of-specification investigations, Phase 1 laboratory investigation, Phase 2 full investigation, assignable cause determination, batch disposition, and what FDA inspectors actually examine.
A complete guide to analytical method transfer between laboratories, the transfer protocol structure, transfer approaches (comparative testing, revalidation, co-validation), acceptance criteria statistics, handling failures, and how to document transfers for regulatory submissions.
A working guide to analytical method validation, the performance characteristics required by ICH Q2(R2), how to design studies for each, what acceptance criteria to set, and how to generate a validation report that holds up under regulatory scrutiny.
What a mature enterprise-level data integrity program actually looks like, system inventory and criticality tiering, governance model, data-flow mapping, risk assessment methodology, and how to measure where you are against where you need to be.
How to design and operate a data governance program, system inventory, criticality tiering, data ownership, data-flow mapping, and the organizational structure that sustains it.
A practical guide to managing changes in a validated environment, impact assessment, revalidation scope determination, documentation requirements, and the difference between changes that need full revalidation vs. those that need a brief confirmation test.
How to approach validation for cloud-hosted and SaaS GxP systems, what IaaS, PaaS, and SaaS mean for validation scope, the shared responsibility model, and what your quality agreement must cover.
A practitioner's guide to the full set of computer system validation documents, URS, FRS, IQ/OQ/PQ protocols, RTM, validation plan and report, and what each one is actually trying to accomplish.
A working guide to validation risk assessment, FMEA, risk ranking matrices, criticality determination, GAMP 5 software categorization, and how to use risk to set your testing scope without over-validating or under-validating.
A practical roadmap for anyone starting a career in pharmaceutical quality, validation, or data integrity, what the field is, what employers are looking for, how to learn it, and what a career progression actually looks like.
How to start a career in pharmaceutical quality, CSV, data integrity, or validation, what to learn first, what credentials matter, and the honest path from zero to employed in regulated biotech.
What FDA 483 observations actually mean, what makes a response effective vs. inadequate, and how to structure a Warning Letter remediation that closes the matter rather than escalating it.
A practitioner's comparison of FDA and EMA inspection approaches, how they differ in structure, investigator authority, inspection scope, enforcement tools, and what each agency focuses on during data integrity assessments. For compliance directors managing global facilities.
How to structure an effective FDA 483 response, root cause analysis depth, CAPA commitments, realistic timelines, and the difference between responses that close observations and responses that don't.
Analysis of recurring failure modes across FDA data integrity enforcement actions, what inspectors actually find, and what the underlying system failures look like.
What inspection readiness actually means, how to prepare a site for FDA or EMA inspection without theater, what inspectors are looking for, and how front room/back room operations actually work.
What FDA inspection readiness actually means, not a sprint before an announced inspection, but maintaining systems that would survive one at any time. Covers inspection logistics, front room/back room, SME preparation, and how data integrity is assessed during an inspection.
A complete guide to designing and running a GxP internal audit program, the annual audit schedule, audit preparation, execution techniques, finding classification, CAPA linkage, and how to make internal audits genuinely useful rather than performative.
A practical guide to GxP supplier qualification, the approved vendor list, qualification levels, audit programs, ongoing monitoring, and how to manage supplier qualification for cloud and SaaS vendors under 21 CFR Part 11.
How data integrity requirements apply to manufacturing automation systems, MES, electronic batch records, SCADA, DCS, PLCs, and historians. Where the compliance gaps are and how to address them.
How the major GxP informatics systems, MES, SCADA, DCS, PLC, historians, LIMS, ELN, and CDS, generate and manage regulated data, their specific data integrity risks, and how 21 CFR Part 11 applies on the shop floor.
How USP <1058> defines analytical instrument qualification, the four Qs, instrument groups A/B/C, and how AIQ connects to computer system validation and data integrity requirements.
A clear breakdown of the equipment qualification lifecycle, Design Qualification through Performance Qualification, what each phase is testing, where programs most commonly fail, and how this connects to data integrity.
The mechanics of GxP audit trails, what to capture, how to configure it correctly, how to review it effectively, and how inspectors use it to find data integrity problems.
How pharmaceutical data moves through its full lifecycle, and where integrity breaks down at each stage. Static vs dynamic records, original vs true copy, and why metadata is part of the record.
FDA's final CSA guidance (February 2026), what it actually requires, how it changes testing scope, scripted vs exploratory testing, using supplier evidence, and what the finalization means for inspection expectations.
A practical breakdown of 21 CFR Part 11 and EU Annex 11, what they require, how they differ, open vs closed systems, electronic signatures, and what actually gets cited in inspections.
How GAMP 5 (2022) works in practice, software categories, the V-model, risk-based validation, and what the second edition changed. For practitioners who need to understand the standard, not just cite it.
How to apply ICH Q9(R1) quality risk management in practice, FMEA, risk ranking, risk assessment methodology, and when to use which tool. Written for practitioners who need to apply this, not just cite it.
How to design and manage a GxP training program that meets regulatory requirements, creates defensible training records, and, critically, actually teaches people to work compliantly. Covers curriculum design, effectiveness checks, LMS requirements, and what inspectors examine.
CAPA is the backbone of every quality management system. This guide explains what CAPA is, when it's triggered, how to run one, and what separates an effective CAPA from a compliance checkbox.
How GMP deviations work from first report through closure, classification criteria, investigation requirements, impact assessment, and what distinguishes a thorough investigation from a compliance exercise.
What ICH Q10 actually requires, how QMS elements connect to GMP compliance, and how data integrity, CSV, and quality culture fit into a coherent quality system design.
A complete guide to GxP document control, the document lifecycle, SOP structure, version control, effective dates, training linkage, and what inspectors look for.
Every major computerized system used in pharmaceutical manufacturing and clinical operations, what each one does, the GxP data it generates, and the validation requirements that come with it.
A complete breakdown of ALCOA+, what each principle actually means, where programs fail, and how to assess compliance in practice.
A ground-level introduction to pharmaceutical data integrity, what it actually means, why regulators treat it as a quality-critical issue, and what the real cost of failure looks like.
A practical map of every quality and compliance role in a regulated organization, what each function owns, how they interact, and what a day in each role actually looks like.
GMP explained without the bureaucratic fog. What the regulations actually require, why they exist, and how they shape every activity in a regulated manufacturing facility.